Micofin (terbinafine) tablets 250 mg. №14

$39.00

Fungal infections of the skin and nails caused by Trichophyton (eg T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum. 1. Ringworm (trichophytia of smooth skin, trichophytia of the perineum and dermatophytia of the feet), when the location of the lesion, the severity or prevalence of infection determine the appropriateness of oral therapy. 2. Onychomycosis.

Category:

Description

Micofin composition
active substance: terbinafine;
1 tablet contains terbinafine hydrochloride equivalent to terbinafine 250 mg;
Excipients: hypromellose, croscarmellose sodium, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate.

Dosage form
Tablets.

Pharmacological properties
Micofin belongs to the group of drugs for the treatment of mycoses.
The main active component of terbinafine is synthetic allylamine, which is highly effective against various dermatophyte fungi.
In particular, it is active against trichophytosis, tonsurans, verrucosum, microsporum, pityrosporum, candida, epidermophytosis, and other types of dermatophyte fungi.
When used in small doses, it has a fungicidal effect against dimorphic, mold and dermatophytes.
Relative to Candida fungi, it produces both fungicidal and fungistatic effects.
Able to influence the early stage of biosynthesis of one of the most important components of fungal cell membranes – ergosterols. As a result, there is a shortage of egosterols and the accumulation of squalene inside the cell. As a result, the death of the fungal cell occurs.
It has a low degree of absorption into the body.

Indication
Fungal infections of the skin and nails caused by Trichophyton (eg T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis and Epidermophyton floccosum.

  • ringworm (trichophytia of smooth skin, trichophytia of the perineum and dermatophytia of the feet), when the location of the lesion, the severity or prevalence of infection determine the appropriateness of oral therapy.
  • onychomycosis.

Contraindication
Hypersensitivity to terbinafine or to any of the excipients.

Children
Data on the use of the drug in children are limited, so its use is not recommended for this age group of patients.

Use during pregnancy or breastfeeding
No toxic effects of the drug on the fetus and fertility were detected. Experience with the drug in pregnant women is very limited, so Mycofin should not be prescribed during pregnancy, unless the clinical condition of the woman requires treatment with oral terbinafine and the expected benefit to the mother outweighs any potential risk to the fetus.
Terbinafine passes into breast milk, so women who are breast-feeding should not be prescribed Mycofin.

Method of application and dosage
The drug Micofin is intended for oral administration.
Adults are prescribed 1 tablet of 250 mg 1 time per day.
The duration of treatment depends on the nature and severity of the disease.

Skin infections
Recommended duration of treatment:

  • dermatophytosis of the feet (interdigital, plantar / type “moccasins”) – 2-6 weeks;
  • trichophytia of smooth skin – 4 weeks;
  • perineal trichophytia – from 2 to 4 weeks.

Complete disappearance of symptoms of infection may occur only a few weeks after the detection of the absence of pathogens by laboratory monitoring.

Onychomycosis
The duration of treatment for most patients is from 6 weeks to 3 months. Periods of treatment lasting less than 3 months may last in patients with toenails, toenails other than the big toe, or in younger patients. In the treatment of toenail lesions, 3 months is usually sufficient, although some patients may require treatment lasting 6 months or longer. Patients who require longer treatment can be identified by the reduced rate of nail growth during the first weeks of treatment.
Complete disappearance of symptoms of infection may occur only a few weeks after the detection of the absence of pathogens by laboratory monitoring.

Overdose
Several cases of overdose (oral administration of up to 5 g of terbinafine) are known. Headache, nausea, epigastric pain and dizziness were noted.
Treatment recommended in case of overdose includes withdrawal of the drug, primarily with activated charcoal and, if necessary, the use of symptomatic maintenance therapy.

Side effects:

  • Disorders of the blood and lymphatic system: neutropenia, agranulocytosis, thrombocytopenia.
  • Immune system disorders: anaphylactoid reactions (including Quincke’s edema), cutaneous and systemic lupus erythematosus.
  • Metabolism and nutrition disorders: decreased appetite.
  • Nervous system disorders: headache, taste disturbance, including loss of taste, which usually resumes within a few weeks after stopping the drug.
  • Gastrointestinal disorders: gastrointestinal symptoms (feeling of fullness, dyspepsia, nausea, abdominal pain, diarrhea).

Expiration date
3 years.

Storage conditions
Store Micofin at a temperature not exceeding 25 ° C.
Keep out of reach of children.